Over the last few years, the use of glucagon-like peptide-1 receptor agonists (GLP-1 agonists) for managing type 2 diabetes has dramatically increased
Ongoing and future clinical trials are expected to further define the cardiovascular role of GLP-1 RAs, expand their therapeutic indications, and solidify their place in the evolving landscape of cardiovascular care
Monitoring temperature changes and discussing any concerns with a healthcare provider ensures that the medications benefits outweigh any potential side effects
Since theres less risk of bacterial infection when youre applying medication to these areas, they arent required to be prepared in a sterile lab
Targets both GLP-1 and GIP receptors Greater average weight loss than Semaglutide in clinical trials Reduces appetite and improves metabolic function Weekly self-injection FDA-approved for chronic weight management Tirzepatide at Bloom Aesthetics + Wellness $749 for a 10-week program
Most patients begin to see weight loss after their dose has been increased one to two times, typically within a month